{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:11:27Z","timestamp":1794978687418,"version":"4.9.1"},"reference-count":27,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["T32CA009615"],"award-info":[{"award-number":["T32CA009615"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Teclistamab is an anti-CD3-\/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed\/refractory multiple myeloma. We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US Multiple Myeloma Immunotherapy Consortium. Among 509 patients, 89% would have been ineligible for the MajesTEC-1 trial, primarily due to prior BCMA-directed therapy, cytopenias, or diminished performance status. Cytokine release syndrome occurred in 54% (1.4% grade \u22653) and immune effector cell\u2013associated neurotoxicity syndrome in 11% (2.2% grade \u22653), with no fatal events. Infections occurred in 42% and contributed to death in 5%. Partial response (PR) or better was achieved in 53% and very good PR or better in 45%. With 10.1 months of median follow-up, the estimated median progression-free survival (PFS) was 5.8 months and 12-month overall survival was 61%. Independent predictors of less than very good PR and shorter PFS included BCMA-directed chimeric antigen receptor T-cell therapy in the previous 9 months, high disease burden, lymphopenia, and elevated ferritin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>T cell\u2013engaging bispecific antibodies such as teclistamab represent an important new treatment modality for multiple myeloma and other blood cancers. This study evaluates the real-world safety and efficacy of teclistamab, including its activity in populations not represented in the initial phase I\/II study, and identifies clinical variables associated with treatment response.<\/jats:p>\n                    <jats:p>See related commentary by Zweegman et al., p. 542<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0354","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T16:07:07Z","timestamp":1752077227000},"page":"561-571","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Real-World Experience with Teclistamab for Relapsed\/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-3315","authenticated-orcid":false,"given":"Beatrice M.","family":"Razzo","sequence":"first","affiliation":[{"name":"1Division of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"2Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-5507","authenticated-orcid":false,"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[{"name":"4Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-1771","authenticated-orcid":false,"given":"Ariel F.","family":"Grajales-Cruz","sequence":"additional","affiliation":[{"name":"5H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8234-6755","authenticated-orcid":false,"given":"Andre","family":"De Menezes Silva Corraes","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Mayo Clinic, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2565-1092","authenticated-orcid":false,"given":"Patrick","family":"Costello","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0623-2561","authenticated-orcid":false,"given":"Yuxin","family":"Liu","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":false,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-7975","authenticated-orcid":false,"given":"Danai","family":"Dima","sequence":"additional","affiliation":[{"name":"4Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[{"name":"4Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-7094","authenticated-orcid":false,"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[{"name":"4Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-8557","authenticated-orcid":false,"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[{"name":"7Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Simmons Comprehensive Cancer Center,UT Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"7Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Simmons Comprehensive Cancer Center,UT Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5462-4991","authenticated-orcid":false,"given":"Alex","family":"Lieberman-Cribbin","sequence":"additional","affiliation":[{"name":"8Mount Sinai School of Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-6536","authenticated-orcid":false,"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[{"name":"8Mount Sinai School of Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9089-5239","authenticated-orcid":false,"given":"Anmol","family":"Goyal","sequence":"additional","affiliation":[{"name":"9Stanford University, Palo Alto, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"10Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-4856","authenticated-orcid":false,"given":"Christopher J.","family":"Ferreri","sequence":"additional","affiliation":[{"name":"10Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"10Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9193-0059","authenticated-orcid":false,"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[{"name":"11Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"11Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[{"name":"11Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2111-2461","authenticated-orcid":false,"given":"Kelley L.","family":"Julian","sequence":"additional","affiliation":[{"name":"12Huntsman Cancer Institute, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3248-7530","authenticated-orcid":false,"given":"Peter A.","family":"Forsberg","sequence":"additional","affiliation":[{"name":"13University of Colorado, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[{"name":"14Roswell Park Comprehensive Cancer Comprehensive Center, Buffalo, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo D.","family":"Parrondo","sequence":"additional","affiliation":[{"name":"16Division of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Mayo Clinic, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-7174","authenticated-orcid":false,"given":"Anna","family":"Chen","sequence":"additional","affiliation":[{"name":"1Division of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2518","authenticated-orcid":false,"given":"Sandra P.","family":"Susanibar-Adaniya","sequence":"additional","affiliation":[{"name":"1Division of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"17Taussig Cancer Institute, Cleveland Clinic, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2265","authenticated-orcid":false,"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[{"name":"17Taussig Cancer Institute, Cleveland Clinic, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"17Taussig Cancer Institute, Cleveland Clinic, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2643-7840","authenticated-orcid":false,"given":"Mariola","family":"Vazquez-Martinez","sequence":"additional","affiliation":[{"name":"5H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[{"name":"5H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[{"name":"12Huntsman Cancer Institute, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[{"name":"18Medical University of South Carolina, Charleston, South Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9914-5628","authenticated-orcid":false,"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[{"name":"8Mount Sinai School of Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-1873","authenticated-orcid":false,"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[{"name":"19University of Kansas Medical Center, Kansas City, Kansas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5670-0186","authenticated-orcid":false,"given":"Jenny","family":"Bhurtel","sequence":"additional","affiliation":[{"name":"19University of Kansas Medical Center, Kansas City, Kansas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-2167","authenticated-orcid":false,"given":"Wei-Ting","family":"Hwang","sequence":"additional","affiliation":[{"name":"20Department of Biostatistics, Epidemiology, and Informatics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"5H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"9Stanford University, Palo Alto, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5748","authenticated-orcid":false,"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[{"name":"1Division of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-4292","authenticated-orcid":false,"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[{"name":"8Mount Sinai School of Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2025111113463777900_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"2025111113463777900_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2025111113463777900_bib3","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025111113463777900_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"2025111113463777900_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025111113463777900_bib6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3324\/haematol.2024.286118","article-title":"Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program","volume":"110","author":"Perrot","year":"2025","journal-title":"Haematologica"},{"key":"2025111113463777900_bib7","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025111113463777900_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"2025111113463777900_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"2025111113463777900_bib10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2025111113463777900_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"2025111113463777900_bib12","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025111113463777900_bib13","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"2025111113463777900_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"2025111113463777900_bib15","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"key":"2025111113463777900_bib16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"2025111113463777900_bib17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"key":"2025111113463777900_bib18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"2025111113463777900_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"2025111113463777900_bib20","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"2025111113463777900_bib21","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"2025111113463777900_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2025111113463777900_bib23","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"2025111113463777900_bib24","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"2025111113463777900_bib25","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","article-title":"Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients","volume":"108","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"key":"2025111113463777900_bib26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.32614\/RJ-2021-053","article-title":"Reproducible summary Tables with the gtsummary package","volume":"13","author":"Sjoberg","year":"2021","journal-title":"R J"},{"key":"2025111113463777900_bib27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41409-019-0679-x","article-title":"Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians","volume":"55","author":"Gauthier","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0354\/3628709\/bcd-24-0354.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0354\/3639231\/bcd-24-0354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/561\/3663377\/bcd-24-0354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/561\/3663377\/bcd-24-0354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:46:44Z","timestamp":1762886804000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/6\/561\/766815\/Real-World-Experience-with-Teclistamab-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7,9]]},"published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0354","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8125996","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.30516439","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516415","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516403","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593209","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516445","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516433","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516421","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593227","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593215","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593245","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593233","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593221","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593251","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516418","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516406","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516448","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516436","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516424","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516412","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516400","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593218","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593206","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516442","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516430","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593248","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593236","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593224","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593242","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30593230","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]}}}